呼吸

订阅

MedSci主页 / 所有栏目 / 呼吸

FDA批准预填充自动注射器Fasenra治疗哮喘

2019-10-05 Allan MedSci原创

FasenraFDA哮喘
关注

阿斯利康近日宣布，FDA已批准预填充自动注射器Fasenra（benralizumab）治疗严重嗜酸性粒细胞性哮喘，通过这项疗法，患者可以进行自我管理。该公司指出，Fasenra最初于2017年在美国获得批准，用于治疗具有嗜酸性表型的12岁及以上的重度哮喘患者。

阿斯利康近日宣布，FDA已批准预填充自动注射器Fasenra（benralizumab）治疗严重嗜酸性粒细胞性哮喘，通过这项疗法，患者可以进行自我管理。该公司指出，Fasenra最初于2017年在美国获得批准，用于治疗具有嗜酸性表型的12岁及以上的重度哮喘患者。

阿斯利康公司生物制药研发执行副总裁Mene Pangalos表示：“Fasenra是唯一在初始加载剂量后每八周就可以服用的呼吸道生物制剂。这项批准意味着重度嗜酸性哮喘患者可以便捷地使用Fasenra”。该公司还指出，继7月份欧洲药品管理局（EMA）人用药品委员会的正面评价之后，欧盟已批准预填充自动注射器Fasenra治疗哮喘。


原始出处：

http://www.firstwordpharma.com/node/1671730#axzz61Rlned4y

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2057983, encodeId=90fc205e98360, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Thu Sep 03 20:40:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839727, encodeId=573f1839e27be, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Aug 01 20:40:00 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701480, encodeId=ab6f1e0148057, content=<a href='/topic/show?id=28b7649e927' target=_blank style='color:#2F92EE;'>#注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64979, encryptionId=28b7649e927, topicName=注射器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bac630379418, createdName=marongnuan, createdTime=Wed Apr 29 14:40:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271171, encodeId=c51b12e1171d1, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Mon Oct 07 02:40:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2020-09-03 gracezdd

    #FAS#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2057983, encodeId=90fc205e98360, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Thu Sep 03 20:40:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839727, encodeId=573f1839e27be, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Aug 01 20:40:00 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701480, encodeId=ab6f1e0148057, content=<a href='/topic/show?id=28b7649e927' target=_blank style='color:#2F92EE;'>#注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64979, encryptionId=28b7649e927, topicName=注射器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bac630379418, createdName=marongnuan, createdTime=Wed Apr 29 14:40:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271171, encodeId=c51b12e1171d1, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Mon Oct 07 02:40:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2020-08-01 bugit

    #FDA批准#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2057983, encodeId=90fc205e98360, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Thu Sep 03 20:40:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839727, encodeId=573f1839e27be, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Aug 01 20:40:00 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701480, encodeId=ab6f1e0148057, content=<a href='/topic/show?id=28b7649e927' target=_blank style='color:#2F92EE;'>#注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64979, encryptionId=28b7649e927, topicName=注射器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bac630379418, createdName=marongnuan, createdTime=Wed Apr 29 14:40:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271171, encodeId=c51b12e1171d1, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Mon Oct 07 02:40:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2020-04-29 marongnuan

    #注射器#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2057983, encodeId=90fc205e98360, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Thu Sep 03 20:40:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839727, encodeId=573f1839e27be, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Aug 01 20:40:00 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701480, encodeId=ab6f1e0148057, content=<a href='/topic/show?id=28b7649e927' target=_blank style='color:#2F92EE;'>#注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64979, encryptionId=28b7649e927, topicName=注射器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bac630379418, createdName=marongnuan, createdTime=Wed Apr 29 14:40:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271171, encodeId=c51b12e1171d1, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Mon Oct 07 02:40:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2019-10-07 zhangxingru

    #Fasenra#

    0

相关资讯

阿斯利康的Fasenra未达到晚期COPD研究的主要目标

阿斯利康公司周五（2018年5月11日）报道，用于中度至极重度慢性阻塞性肺疾病（COPD）患者治疗的Fasenra（benralizumab）的III期GALATHEA研究未能达到显著降低症状的主要终点

欧盟批准AZ的Fasenra治疗严重哮喘

阿斯利康(AstraZeneca)的biologic Fasenra在欧洲被批准用于治疗严重嗜酸粒细胞性哮喘。具体而言，尽管高剂量吸入皮质类固醇加长效β受体激动剂，但该药物的标签允许其在成人中的使用得到充分控制。阿斯利康说，Fasenra（benralizumab）是第一个获得批准的呼吸类生物制剂，它是一种招募自然杀伤细胞以消耗嗜酸性粒细胞的单克隆抗体，在体内维持药效的时间长达八周。批准是基于WI

NEJM：Fasenra符合嗜酸性粒细胞增多症中期研究的主要目标

阿斯利康近日表示，在《NEJM》发表的II期研究结果表明，大部分接受Fasenra（贝那利珠单抗）治疗的嗜酸性粒细胞增多症（HES）患者的绝对血液嗜酸性粒细胞计数至少下降一半。

嗜酸性粒细胞性食管炎：Fasenra被FDA授予孤儿药物资格

阿斯利康近日宣布，美国FDA已经授予其Fasenra（贝那利珠单抗）孤儿药物资格，用以治疗嗜酸性粒细胞性食管炎。